MX2022004220A - Recombinant live immunogenic composition comprising newcastle disease virus (ndv) expressing the s1 subunit and the rbd of the spike protein of sars-cov-2. - Google Patents

Recombinant live immunogenic composition comprising newcastle disease virus (ndv) expressing the s1 subunit and the rbd of the spike protein of sars-cov-2.

Info

Publication number
MX2022004220A
MX2022004220A MX2022004220A MX2022004220A MX2022004220A MX 2022004220 A MX2022004220 A MX 2022004220A MX 2022004220 A MX2022004220 A MX 2022004220A MX 2022004220 A MX2022004220 A MX 2022004220A MX 2022004220 A MX2022004220 A MX 2022004220A
Authority
MX
Mexico
Prior art keywords
cov
sars
rbd
subunit
ndv
Prior art date
Application number
MX2022004220A
Other languages
Spanish (es)
Inventor
Diaz Manolo Clemente Fernandez
Mayo Katherine Ivette Calderon
Neyra Aldo Stanlee Rojas
Original Assignee
Farm Veterinarios S A C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farm Veterinarios S A C filed Critical Farm Veterinarios S A C
Publication of MX2022004220A publication Critical patent/MX2022004220A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Abstract

The present invention relates to the obtainment of two live recombinant or vectored NDV vaccines expressing the S1 subunit and the RBD of the S protein of SARS-CoV-2 which, when applied intranasally in a hamster animal model, generate the production of neutralising antibodies against SARS-CoV-2. The invention also shows that these live vaccines are compatible for combined use with each other to induce the production of neutralising antibodies against SARS-CoV-2 without substantial cross-interference, indicating a synergy between the two vaccines, wherein recombinant NDV viruses (rNDV-LS1-HN-RBD/SARS-CoV-2 (SEQ ID No. 7) and rNDV-LS1-S1-F/SARS-CoV-2 (SEQ ID No. 13) express the S1 subunit and the RBD of the S protein of SARS-CoV-2 in mammals.
MX2022004220A 2021-01-08 2022-01-04 Recombinant live immunogenic composition comprising newcastle disease virus (ndv) expressing the s1 subunit and the rbd of the spike protein of sars-cov-2. MX2022004220A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PE2021000033A PE20210318A1 (en) 2021-01-08 2021-01-08 RECOMBINANT LIVE IMMUNOGENIC COMPOSITION INCLUDING NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND THE SPIKE PROTEIN RBD OF SARS-COV-2
PCT/IB2022/050031 WO2022149058A1 (en) 2021-01-08 2022-01-04 Recombinant live immunogenic composition comprising newcastle disease virus (ndv) expressing the s1 subunit and the rbd of the spike protein of sars-cov-2

Publications (1)

Publication Number Publication Date
MX2022004220A true MX2022004220A (en) 2022-08-08

Family

ID=74855966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004220A MX2022004220A (en) 2021-01-08 2022-01-04 Recombinant live immunogenic composition comprising newcastle disease virus (ndv) expressing the s1 subunit and the rbd of the spike protein of sars-cov-2.

Country Status (7)

Country Link
AR (1) AR124522A1 (en)
BR (1) BR112022016492A2 (en)
CO (1) CO2022010353A2 (en)
EC (1) ECSP22064620A (en)
MX (1) MX2022004220A (en)
PE (1) PE20210318A1 (en)
WO (1) WO2022149058A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20135924B (en) * 2005-12-02 2013-10-10 The Mount Sinai School Of Medicine Of New York Univ Chimeric viruses presenting non-native surface proteins and usage thereof
WO2021229270A1 (en) * 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Recombinant vaccine against covid-19 in a viral vector
CN112011521A (en) * 2020-06-15 2020-12-01 浙江迪福润丝生物科技有限公司 Novel recombinant newcastle disease virus vector coronavirus vaccine candidate strain as well as construction method and application thereof

Also Published As

Publication number Publication date
PE20210318A1 (en) 2021-02-16
CO2022010353A2 (en) 2022-08-09
BR112022016492A2 (en) 2023-10-31
AR124522A1 (en) 2023-04-05
ECSP22064620A (en) 2022-09-30
WO2022149058A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
NZ735684A (en) Materials and methods for respiratory disease control in canines
WO2006115843A3 (en) Nipah virus vaccines
EP2998315A3 (en) Newcastle disease virus vectored avian vaccines
MY191634A (en) Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
WO2008156778A3 (en) Influenza m2 protein mutant viruses as live influenza attenuated vaccines
MX2011006846A (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
JP2019506175A5 (en)
ES2531290T3 (en) Transferases and oxidoreductases, nucleic acids that encode them and methods to prepare and use them
RS20080174A (en) Canine influenza virus and related compositions and methods of use
JP2016509011A5 (en)
UA110328C2 (en) Recombinant vaccine based on avian paramixoviruses and method for its preparation and administration
AR094725A1 (en) PARVOVIRUS 5A PORCINO, METHODS OF USE AND VACCINE
PH12019500592A1 (en) New swine influenza vaccine
PE20091355A1 (en) ATTENUATED ONCOLYTIC PARAMYXOVIRUSES CODING CYTOKINES OF BIRDS
PH12020551637A1 (en) Additives for protein formulations to improve thermal stability
WO2018097603A3 (en) Middle east respiratory syndrome coronavirus s protein immunogenic composition and method for preparing same
MX2023000041A (en) Compositions and methods for inducing an immune response against coronavirus.
PH12017502380A1 (en) Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
EA201790296A1 (en) VACCINE IN THE FORM OF A RECOMBINANT VECTOR BASED ON THE BIRD OF THE SEROTIP 9
MX2021012695A (en) Csfv subunit vaccine.
CO6700818A2 (en) Parapoxvirus Vectors
MX2022004220A (en) Recombinant live immunogenic composition comprising newcastle disease virus (ndv) expressing the s1 subunit and the rbd of the spike protein of sars-cov-2.
Verjan et al. A soluble nonglycosylated recombinant infectious hematopoietic necrosis virus (IHNV) G-protein induces IFNs in rainbow trout (Oncorhynchus mykiss)
AR081409A1 (en) RECOMBINING PARAPOXVIRUS CONTAINING HETEROLOGICAL DNA DERIVED FROM A RABIA VIRUS (RV)
WO2018115509A3 (en) New flavivirus vaccine